BACKGROUND: The efficacy of vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix has been questioned after publication of the OPPTIMUM study. OBJECTIVE: To determine whether vaginal progesterone prevents preterm birth and improves perinatal outcomes in asymptomatic women with a singleton gestation and a midtrimester sonographic short cervix. STUDY DESIGN: We searched MEDLINE, EMBASE, LILACS, and CINAHL (from their inception to September 2017); Cochrane databases; bibliographies; and conference proceedings for randomized controlled trials comparing vaginal progesterone vs placebo/no treatment in women with a singleton gestation and a midtrimester sonographic cervical length 25 mm. This was a systematic review and meta-analysis of individual patient data. The primary outcome was preterm birth <33 weeks of gestation. Secondary outcomes included adverse perinatal outcomes and neurodevelopmental and health outcomes at 2 years of age. Individual patient data were analyzed using a 2-stage approach. Pooled relative risks with 95% confidence intervals were calculated. Quality of evidence was assessed using the GRADE methodology. RESULTS: Data were available from 974 women (498 allocated to vaginal progesterone, 476 allocated to placebo) with a cervical length 25 mm participating in 5 high-quality trials. Vaginal progesterone was associated with a significant reduction in the risk of preterm birth <33 weeks of gestation (relative risk, 0.62; 95% confidence interval, 0.47e0.81; P ¼ .0006; high-quality evidence). Moreover, vaginal progesterone significantly decreased the risk of preterm birth <36, <35, <34, <32, <30, and <28 weeks of gestation; spontaneous preterm birth <33 and <34 weeks of gestation; respiratory distress syndrome; composite neonatal morbidity and mortality; birthweight <1500 and <2500 g; and admission to the neonatal intensive care unit (relative risks from 0.47-0.82; high-quality evidence for all). There were 7 (1.4%) neonatal deaths in the vaginal progesterone group and 15 (3.2%) in the placebo group (relative risk, 0.44; 95% confidence interval, 0.18e1.07; P ¼ .07; low-quality evidence). Maternal adverse events, congenital anomalies, and adverse neurodevelopmental and health outcomes at 2 years of age did not differ between groups. CONCLUSION: Vaginal progesterone decreases the risk of preterm birth and improves perinatal outcomes in singleton gestations with a midtrimester sonographic short cervix, without any demonstrable deleterious effects on childhood neurodevelopment.
Introduction
Every year, an estimated 15 million babies are born preterm worldwide with rates ranging from 5% in several European countries to 18% in some African countries. 1 In 2015, the preterm birth rate in the United States, which had declined from 2007 through 2014, increased slightly to 9.63%. 2 Globally, preterm birth complications are the leading cause of child mortality, responsible for nearly 1 million deaths in 2013. 3 Additionally, surviving preterm babies are at greater risk for short-term health complications that may include acute respiratory, gastrointestinal, infectious, central nervous system, hearing, and vision problems, and for longterm neurodevelopmental disabilities such as cerebral palsy and impaired learning and visual disorders as well as chronic diseases in adulthood. [4] [5] [6] [7] [8] Preterm parturition is a syndrome caused by multiple etiological factors such as intraamniotic infection, extrauterine infections, vascular disorders, decidual senescence, disruption of maternal-fetal tolerance, a decline in progesterone action, uterine overdistension, cervical disease, or maternal stress.
9-11 A short cervix, conventionally defined as a transvaginal sonographic cervical length 25 mm in the midtrimester of pregnancy, is a powerful risk factor for spontaneous preterm birth and has a high predictive accuracy for spontaneous preterm birth <34 weeks of gestation and a moderate to low predictive accuracy for spontaneous preterm birth <37 weeks of gestation in both singleton and twin gestations. In 2012, a systematic review and metaanalysis of individual patient data (IPD) from randomized controlled trials comparing vaginal progesterone vs placebo in women with a singleton gestation and a cervical length 25 mm in the midtrimester 49 reported that the administration of vaginal progesterone was associated with a significant reduction in the risk of preterm birth occurring from <28 weeks of gestation through <35 weeks of gestation. In addition, vaginal progesterone administration was associated with a reduction in the risk of admission to the neonatal intensive care unit (NICU), respiratory distress syndrome (RDS), composite neonatal morbidity and mortality, and birthweight <1500 g. Since the publication of that IPD meta-analysis, vaginal progesterone has been recommended for patients with a singleton gestation and a short cervix by the Society for MaternalFetal Medicine, 50 the American Congress of Obstetricians and Gynecologists, 51 the International Federation of Gynecology and Obstetrics, 52 and the National Institute for Health and Care Excellence, 53 among others. In 2016, the findings of the OPPTIMUM study were reported. This was a randomized controlled trial comparing vaginal progesterone vs placebo in women at risk of preterm birth because of previous spontaneous preterm birth <34 weeks of gestation, a cervical length 25 mm, or a positive fetal fibronectin test combined with other clinical risk factors for preterm birth. 54 The results of that trial showed that vaginal progesterone did not significantly reduce the risk of preterm birth or perinatal morbidity and mortality either in the entire population or in the subgroup of women with a cervical length 25 mm. That report created confusion among clinicians and professional/scientific organizations regarding the clinical efficacy of vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix. 55, 56 Therefore, we performed a meta-analysis of aggregate data that assessed the effect of vaginal progesterone on the risk of preterm birth 34 weeks or fetal death in women with a singleton gestation and a cervical length 25 mm, the only outcome measure for which the publication of the OPPTI-MUM study reported complete data in this subpopulation of women. 57 That meta-analysis showed that vaginal progesterone significantly reduced the risk of preterm birth 34 weeks or fetal death by 34%. Subsequently, the lead author of the OPPTIMUM study provided us the individual data for all women with a cervical length 25 mm who were included in that trial. Therefore, the objective of this systematic review and IPD meta-analysis was to assess the efficacy of vaginal progesterone in reducing the risk of preterm birth and adverse perinatal outcomes in asymptomatic women with a singleton gestation and a short cervix (cervical length 25 mm).
Materials and Methods
The study was prospectively registered with the PROSPERO database of systematic reviews (no. CRD42017057155) and reported in accordance with the PRISMA-IPD statement. 58 
Search strategy and selection criteria
We searched MEDLINE, EMBASE, LILACS, CINAHL, the Cochrane Central Register of Controlled Trials, and research registers of ongoing trials (all from inception to Sept. 30, 2017) , and Google Scholar using the key words "progesterone" and "preterm birth" to identify all randomized controlled trials comparing vaginal progesterone (any dose) vs placebo/no treatment for the prevention of preterm birth and/or adverse perinatal outcomes in women with a singleton gestation. No language restrictions were imposed. We also searched in proceedings of congresses/ meetings on maternal-fetal medicine and bibliographies of the retrieved articles, and contacted investigators in the field to locate unpublished studies. Trials were eligible if the primary aim of the study was to prevent preterm birth in women with a "short cervix," or to prevent preterm birth in women with risk factors other than a short cervix but for whom outcomes were available in those with a prerandomization cervical length 25 mm. Quasirandomized trials, trials that assessed vaginal progesterone in women with threatened or arrested preterm labor, and trials in which vaginal progesterone was administered in the first trimester to prevent miscarriage were excluded from the review. Two authors (R.R. and A.C-A.) independently assessed all the potential studies identified in the literature search for eligibility. Disagreements about inclusion were resolved through discussion.
Data collection
The principal investigators of eligible trials were contacted and asked to share their data for this collaborative project.
Authors were supplied with a data extraction sheet and requested to provide anonymized data about baseline characteristics, interventions, and outcomes for each randomized patient in the trial. Data provided by the investigators were systematically checked for completeness, duplication, consistency, feasibility, and integrity of randomization. In addition, the results from the review's analysis were cross-checked against the published reports of the trials. Authors were contacted for clarification where discrepancies existed and asked to supply missing data when necessary. Once queries had been resolved, clean data were uploaded to the main study database.
Outcome measures
As in the previous IPD meta-analysis, 49 the primary outcome was preterm birth <33 weeks of gestation. Secondary outcomes were preterm birth <37, <36, <35, <34, <32, <30, and <28 weeks of gestation; spontaneous preterm birth <33 and <34 weeks of gestation; mean gestational age at delivery; RDS; necrotizing enterocolitis; intraventricular hemorrhage; proven neonatal sepsis; bronchopulmonary dysplasia; retinopathy of prematurity; fetal death; neonatal death; perinatal death; composite neonatal morbidity and mortality (RDS, intraventricular hemorrhage, necrotizing enterocolitis, proven neonatal sepsis, or neonatal death); Apgar score <7 at 5 minutes; birthweight <1500 and <2500 g; admission to the NICU; use of mechanical ventilation; congenital anomaly; any adverse maternal event; and the Bayley-III cognitive composite score, moderate or severe neurodevelopmental impairment, visual or hearing impairment, and disability in renal, gastrointestinal, or respiratory function at 2 years of age.
Risk of bias assessment
Assessments of the risk of bias for the included trials were done independently by 2 investigators (R.R. and A.C-A.) according to the 7 domains outlined in the Cochrane Handbook for Systematic Reviews of Interventions (random sequence generation, allocation concealment, blinding of participants and personnel, Reports of Major Impact ajog.org blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases). 59 This tool categorizes studies by low, unclear, or high risk of bias in each domain. When the information was not available in the published paper, the trial's principal investigator was contacted to request clarification or additional information. We resolved any disagreement regarding the risk of bias assessment by consensus.
Data analysis
We analyzed all data on an intention-totreat basis. IPD were analyzed using a 2-stage approach. In the first stage, estimates of effect were derived from the IPD for each trial; in the second stage, these were combined using standard methods for meta-analyses of aggregate data. 60 We calculated the pooled relative risk (RR) for dichotomous data and mean difference for continuous data with an associated 95% confidence interval (CI). Heterogeneity of treatment effect was assessed with the I 2 statistic. 61 Results from individual studies were pooled using a fixed-effects model if substantial statistical heterogeneity was not present (I 2 30%). If I 2 values were >30%, a random-effects model was used to pool data across studies, as recommended by the Cochrane Handbook for Systematic Reviews of Interventions. 59 We calculated the number needed to treat with a 95% CI where meta-analysis of dichotomous outcomes revealed a statistically significant beneficial or harmful effect of vaginal progesterone. 62 Prespecified subgroup analyses were carried out according to obstetrical history (no previous spontaneous preterm birth and at least 1 previous spontaneous preterm birth), cervical length (<10, 10-20, and 21-25 mm), maternal age (<20, 20-34, and 35 years), race/ethnicity (White, Black, Asian, and Other), body mass index (<18.5, 18.5-24.9, 25.0-29.9, and 30 kg/m 2 ), gestational age at treatment initiation (18-21 and 22-25 weeks) , and daily dose of vaginal progesterone (90-100 and 200 mg). Moreover, we performed a post-hoc subgroup analysis according to the country in which women were enrolled (United States vs other countries). A test for interaction between intervention and patient or trial characteristics was calculated to examine whether intervention effects differ between subgroups. [63] [64] [65] An interaction P value .05 was considered to indicate that the effect of intervention did not differ significantly between subgroups. We also planned to explore potential sources of heterogeneity and to assess publication and related biases if at least 10 studies were included in a metaanalysis, but these analyses were not undertaken due to the limited number of trials included in the review. Subgroup analyses were performed only for the primary outcome of preterm birth <33 weeks of gestation. Prespecified sensitivity analyses to explore the impact of selection, performance, and detection biases on results were not carried out because all trials were considered at low risk for these biases. Statistical analyses were performed using Review Manager (Version 5.3.5; Nordic Cochrane Center, Copenhagen, Denmark) and StatsDirect (Version 3.0.198; StatsDirect Ltd, Cheshire, United Kingdom).
Quality of evidence
The quality of the body of evidence relating to primary and secondary outcomes was assessed using the GRADE approach. 66 We used the GRADEpro guideline development tool 67 to import data from Review Manager in order to create "Summary of Findings" tables. The GRADE approach results in an assessment of the quality of evidence in 4 grades: (i) high: we are very confident that the true effect is close to that of the estimate of the effect; (ii) moderate: we are moderately confident in the effect estimate, and the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; (iii) low: our confidence in the effect estimate is limited, and the true effect may be substantially different from the estimate of the effect; and (iv) very low: we have very little confidence in the effect estimate, and the true effect is likely to be substantially different from the estimate of effect. The evidence can be downgraded from high quality by 1 level for serious (or by 2 levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates, or potential publication bias.
This study was exempted from review by the Human Investigation Committee Administration Office of Wayne State University because all included studies were published previously and had each previously received local Institutional Review Board approvals and written consent from participants.
Results

Selection, characteristics, and risk of bias of studies
Literature searches identified 12 randomized controlled trials that compared vaginal progesterone vs placebo 54, [68] [69] [70] [71] [72] [73] [74] [75] [76] or no treatment 77, 78 in singleton gestations with the aim of preventing preterm birth and/or adverse perinatal outcomes ( Figure 1 ). Six studies that assessed vaginal progesterone in women at high risk for preterm birth were excluded for the following reasons: cervical length was not measured or data on cervical length were not collected before randomization, 68, 73, [76] [77] [78] and inclusion of 27 women with a short cervix (defined as a cervical length 28 mm) who underwent cervical cerclage before randomization. 75 We requested IPD for women with a cervical length 25 mm before randomization from the principal investigators of the remaining 6 trials. 54, [69] [70] [71] [72] 74 Data from 1 trial, which compared vaginal progesterone vs placebo in women with a singleton gestation without previous spontaneous preterm birth and a cervical length 30 mm (n ¼ 80), could not be obtained. 74 We estimated that this trial included approximately 35 patients with a cervical length 25 mm. IPD were obtained for 974 women with a cervical length 25 mm from 5 double-blind, placebocontrolled trials; 54, [69] [70] [71] [72] 498 women were assigned to vaginal progesterone and 476 to placebo. Baseline characteristics were largely balanced between the vaginal progesterone and placebo groups ( Table 1) .
The main characteristics of the 5 studies included in the systematic review ajog.org Reports of Major Impact are depicted in Table 2 . Two trials were specifically designed to evaluate the use of vaginal progesterone in women with a short cervix (cervical length 15 mm 69 and cervical length between 10-20 mm 72 ). One tested the effect of vaginal progesterone in women at risk for preterm birth because of previous spontaneous preterm birth, a sonographic cervical length 25 mm, or a positive fetal fibronectin test combined with other clinical risk factors for preterm birth. 54 Another evaluated the use of vaginal progesterone in women with a history of spontaneous preterm birth. 70 The remaining trial examined the use of vaginal progesterone in women with a previous spontaneous preterm birth, uterine malformations, or a twin gestation. 71 Three studies 54, 69, 72 provided 96% of the total sample size of the IPD meta-analysis. The daily dose of vaginal progesterone used in the trials varied from 90-200 mg and the treatment was administered from 18-25 to 34-36 weeks of gestation. An adequate compliance or adherence to treatment (80% of prescribed medication) was reported for >90% of patients participating in 4 trials. [69] [70] [71] [72] In the trial by Norman et al, 54 only 66% of patients with a cervical length 25 mm had a compliance 80%. Four studies [69] [70] [71] [72] were considered to be at low risk of selection, performance, detection, attrition, and reporting biases (Figure 2 ). One study 54 was considered to be at high risk of attrition bias for the childhood primary outcome because information on the Bayley-III cognitive composite score at 2 years of age was available for w70% of surviving children. Moreover, this study was at high risk of compliance bias, which can affect the trial's statistical power to detect the effects of the intervention. 79 
Effect of vaginal progesterone on preterm birth
Vaginal progesterone significantly reduced the risk of preterm birth <33 weeks of gestation (14% vs 22%; RR, 0.62; 95% CI, 0.47e0.81; P ¼ .0006; I 2 ¼ 0%; number needed to treat, 12; 95% CI, 8e23; high-quality evidence) ( Figure 3 ). The frequencies of preterm birth <36, <35, <34, <32, <30, and <28 weeks of gestation and spontaneous preterm birth <33 and <34 weeks of gestation were significantly lower in the vaginal progesterone group (RRs from 0.64-0.80; I 2 ¼ 0 for all; high-quality evidence for all) (Table 3) . Additionally, the mean gestational age at delivery was significantly greater in the vaginal progesterone group than in the placebo group (mean difference, 0.74 weeks; 95% CI, 0.18e1.30). There was no evidence of an effect of vaginal progesterone on preterm birth <37 weeks of gestation (high-quality evidence).
Effect of vaginal progesterone on adverse perinatal and neurodevelopmental outcomes
Treatment with vaginal progesterone was also associated with a significant reduction in the risk of RDS, composite neonatal morbidity and mortality, birthweight <1500 and <2500 g, and admission to the NICU (RRs from 0.47-0.82; I 2 ¼ 0 for all; high-quality evidence for all). The frequency of neonatal death was 1.4% (7/498) in the vaginal progesterone group and 3.2% (15/476) in the placebo group (RR, 0.44; 95% CI, 0.18e1.07; P ¼.07; I 2 ¼ 0%; low-quality evidence). There were no significant Reports of Major Impact ajog.org differences between the study groups in the risk of necrotizing enterocolitis, intraventricular hemorrhage, proven neonatal sepsis, bronchopulmonary dysplasia, retinopathy of prematurity, fetal death, perinatal death, Apgar score <7 at 5 minutes, use of mechanical ventilation, congenital anomalies, and any maternal adverse event (low-to moderate-quality evidence). At 2 years of age, the Bayley-III cognitive composite scores and the frequencies of moderate/ severe neurodevelopmental impairment, visual or hearing impairment, and disability in renal, gastrointestinal, or respiratory function did not differ significantly between the vaginal progesterone and placebo groups (1 study, 54 low-quality evidence for all).
Subgroup analyses
Subgroup analyses of the primary outcome according to maternal and trial characteristics are shown in Figure 4 . There was no evidence of heterogeneity of treatment effect across any of the prespecified variables (all P for interaction .18). The direction of effect favored vaginal progesterone across all strata, although it appeared that the intervention had no effect in women with a cervical length <10 mm. However, the test of interaction among the cervical length groups was not significant (P ¼ . 22) , suggesting that the response to treatment in the cervical length groups was not significantly different. The beneficial effect of vaginal progesterone did not differ significantly between patients with previous spontaneous preterm birth and those with no previous spontaneous preterm birth (P for interaction ¼ .74), as well as between US women and non-US women (P for interaction ¼ .51). Effects favoring the intervention were statistically significant in several subgroups of particular clinical interest, including patients with no previous spontaneous preterm birth, patients with a history of spontaneous preterm birth, and those receiving either 90-100 or 200 mg/d of vaginal progesterone.
Comment
Principal findings of the study
First, women with a singleton gestation and a midtrimester short cervix who received vaginal progesterone had a significant reduction in the risk of preterm birth (<28, <30, <32, <33, <34, <35, and <36 weeks of gestation). Second, vaginal progesterone improved neonatal outcome. Indeed, neonates of mothers who received vaginal progesterone had a significantly lower risk of RDS. Additionally, vaginal progesterone was also associated with a significant decrease in the risk of composite neonatal morbidity and mortality, low birthweight (<2500 g), very low birthweight (<1500 g), and NICU admission. Third, there was a nonsignificant trend toward reduction of neonatal mortality (by 66%, P ¼.07) and use of mechanical ventilation (by 35%, P ¼ .06). Fourth, evidence from one trial 54 showed that, at 2 years of age, there were no significant differences in cognitive scores or the frequency of neurodevelopmental impairment or renal, gastrointestinal, and respiratory morbidity between children exposed prenatally to vaginal progesterone vs placebo. Finally, there were no significant differences in the frequency of maternal adverse events and congenital anomalies between the vaginal progesterone and placebo groups.
Clinical meaning of the findings
A new finding is that vaginal progesterone administered to women with a midtrimester short cervix significantly reduces the risk of preterm birth <36 weeks and birthweight <2500 g. In a previous IPD meta-analysis, vaginal progesterone reduced the rate of preterm birth from <28 to <35 weeks. 49 The extended efficacy in reducing the rate of preterm birth to <36 weeks is probably attributable to the larger sample size of the current meta-analysis. This has important implications as late preterm birth (34-36 6/7 weeks) represents approximately 72% of all preterm births. 80 Vaginal progesterone is expected to reduce neonatal complications by preventing preterm birth. The current IPD meta-analysis shows that vaginal progesterone is significantly associated with a 41% reduction in the frequency of a prespecified composite outcome of neonatal death combined with the most common neonatal complications affecting preterm neonates, such as RDS, intraventricular hemorrhage, necrotizing enterocolitis, and proven neonatal sepsis, which are important to patients, families, and health care providers. This finding is strengthened by the fact that the magnitude of the beneficial effect of vaginal progesterone on the individual components of the composite outcome was consistent with a reduction of about 40-50% for neonatal death, RDS, intraventricular hemorrhage, and proven neonatal sepsis.
The prespecified composite outcome measure did not restrict the endpoint of morbidity to complications that have a very low prevalence, such as severe intraventricular hemorrhage (grades III/ IV), necrotizing enterocolitis (stages II/ III), and retinopathy of prematurity (stages III-V). If the composite outcome measure had been restricted to only ajog.org
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Quality of evidence based on GRADE
We assessed primary and secondary outcomes with GRADE methodology, as shown in Table 4 . Evidence was graded as "high quality" for all outcomes for which vaginal progesterone significantly reduced their risk. A determination of "high quality" signifies that we are very confident that the true effect is close to that of the estimate of the effect, and that further research is very unlikely to change this level of confidence. 66 Evidence for the remaining outcomes was considered to be of moderate to low quality.
Subgroup analysis according to a history of spontaneous preterm birth
This meta-analysis also shows a beneficial effect of vaginal progesterone across a range of subgroups, including patients with or without a previous spontaneous preterm birth.
The results of an indirect comparison meta-analysis concluded that vaginal progesterone and cerclage have a similar efficacy to prevent preterm birth and perinatal morbidity and mortality in patients with a short cervix and a history of preterm birth. 82 The findings reported herein reaffirm that vaginal progesterone should be offered as an alternative to cerclage for patients with a singleton gestation, previous spontaneous preterm birth, and a cervical length 25 mm. 82 
Subgroup analysis according to country of enrollment (United States vs other countries)
In 2012, the US Food and Drug Administration (FDA) reviewed the PREGNANT trial 72 as it considered a New Drug Application (NDA) proposing a pharmaceutical for the treatment of women with a singleton gestation and a midtrimester sonographic short cervix with vaginal progesterone. The application filed by a pharmaceutical company was not approved by the FDA. One of the reasons posited by the FDA was an alleged lack of statistically significant efficacy of vaginal progesterone in women enrolled in the United States.
Recently, Yusuf and Wittes 83 analyzed several examples of regional differences in the results of randomized clinical trials in medicine and provided their assessment as to whether or not such differences are likely to be due to chance. The PREG-NANT trial 72 was one of the examples of variations in results among countries assessed by Yusuf and Wittes 83 (who also examined the post-hoc analysis of the FDA). These investigators concluded that "geography does not trump biology in this case, and we would have applied the overall results of the trial to the US." 83 Consistent with this conclusion by Yusuf and Wittes, 83 a subgroup analysis in the current IPD meta-analysis showed that the beneficial effects of vaginal progesterone on preterm birth <33 weeks of gestation did not differ significantly between women enrolled in the United States (RR, 0.73; 95% CI, 0.42e1.27) and women enrolled outside the United States (RR, 0.59; 95% CI, 0.43e0.80), as the interaction test for subgroup differences was nonsignificant (P ¼ .51).
Subgroup analyses according to vaginal progesterone dose and cervical length
There was no difference in efficacy in the prevention of preterm birth when either 90-100 or 200 mg/d of vaginal progesterone was administered. Therefore, either regimen can be used in practice.
Insofar as cervical length, vaginal progesterone appeared to have no effect on the risk of preterm birth <33 weeks in patients with a cervical length <10 mm. Whether this lack of efficacy has a biological basis, or is a chance finding, is unclear. Although the interaction test for subgroup differences was not significant (P ¼ .22), suggesting that vaginal progesterone has no differential efficacy in the prespecified cervical length groups, it is possible that women with a very short cervix are more likely to have intraamniotic inflammation and may be less responsive to vaginal progesterone. [84] [85] [86] [87] However, we performed a post-hoc subgroup analysis examining the effect of vaginal progesterone on the risk of composite neonatal morbidity and mortality according to cervical length, 
Long-term effects of prenatal exposure to vaginal progesterone
Current evidence suggests that in utero exposure to vaginal progesterone does not have an effect on neurodevelopmental outcomes at least until 2 years of age and, possibly, until 6 years of age. Overall, the OPPTIMUM study 54 found that there were no significant differences in neurodevelopmental outcomes at 2 years of age between children exposed in utero to vaginal progesterone and those exposed to placebo. O'Brien et al 88 assessed neurodevelopmental outcomes at 6, 12, and 24 months of age in children born to women enrolled in their trial 70 and found similar frequencies of suspected developmental delay in the vaginal progesterone and placebo groups. Similar findings have been reported in children born to mothers participating in trials that compared vaginal progesterone and placebo in unselected twin gestations, 89, 90 at a mean age of w56 months. 91, 92 Therefore, there is no evidence that vaginal progesterone has adverse effects on childhood neurodevelopmental outcomes.
Strengths and limitations
A major strength of this study was the inclusion of individual data for most patients (97%) with a singleton gestation and a short cervix randomized to receive vaginal progesterone or placebo in trials that assessed this intervention with the aim of preventing preterm birth. Individual data for approximately 35 patients with a cervical length 25 mm who participated in a trial stopped early due to low enrollment could not be obtained from the investigators. 74 In that trial, vaginal progesterone was associated with a nonsignificant reduction in the risk of composite neonatal morbidity and mortality and preterm birth <32 and <34 weeks of gestation. We performed several simulated meta-analyses by including the results for women with a cervical length 30 mm reported in that study. After assuming the worst-case scenario (all adverse outcomes among patients with a cervical length 25 mm receiving vaginal progesterone and none among patients with a cervical length 25 mm receiving placebo), we found that the inclusion of data from that study in the meta-analyses resulted in minimal changes in the overall estimates of effect size, whereas the beneficial effects of vaginal progesterone on the risk of preterm birth and neonatal morbidity and mortality remained statistically significant. Other strengths of the present study are the absence of clinical and statistical heterogeneity in almost all meta-analyses and the balance in prognostic factors between the vaginal progesterone and placebo groups at baseline, which reduces the possibility of introducing biases in the estimates of intervention effects.
The main limitation of our study was the lack of data on the outcome measure RDS and the use of Reports of Major Impact ajog.org Reports of Major Impact ajog.org mechanical ventilation, because this information was not collected in the OPPTIMUM study. 54 The net effect was a reduction in the sample size of meta-analyses for these outcomes and for the composite outcome of neonatal morbidity and mortality. A second limitation was that some subgroup analyses included a small number of patients, which limits the statistical power to estimate the effects within these subgroups.
RDS is the most common complication of preterm birth; therefore, it is an appropriate endpoint when assessing neonatal morbidity. Similarly, the requirement for mechanical ventilation is an important endpoint, given that it reflects the severity of RDS, and complications may arise during or after mechanical ventilation. Most trials designed to study the effects of interventions in the prevention of preterm birth have also included RDS as a main endpoint. Indeed, even the PROGRESS trial, aimed at determining the effect of vaginal progesterone in patients with a history of preterm birth, used RDS as a primary endpoint. 76 Cost-effectiveness of midtrimester sonographic cervical length and vaginal progesterone in women with a short cervix Several cost-effectiveness studies have shown that the combination of universal transvaginal cervical length screening and vaginal progesterone administration to women with a short cervix is a costeffective intervention that reduces preterm birth and associated perinatal morbidity and mortality, regardless of the cutoff used to define a short cervix in the decision and economic analyses. Cahill et al 93 compared 4 strategies and found that universal cervical length screening to identify women with a cervical length 15 mm and subsequent treatment with vaginal progesterone was the most cost-effective strategy and the dominant choice over the other 3 alternatives: cervical length screening for women at increased risk for preterm birth and treatment with vaginal progesterone; risk-based treatment with 17-alpha hydroxyprogesterone caproate without screening; and no screening or treatment. 93 Werner et al 94 found that universal cervical length screening followed by treatment with vaginal progesterone if cervical length <15 mm could prevent 22 cases of neonatal death or long-term neurologic deficits and save approximately $19.6 million for every 100,000 women screened. In 2015, Werner et al 95 reevaluated the cost-effectiveness of universal transvaginal cervical length screening and vaginal progesterone administration to women with a singleton gestation, no previous spontaneous preterm birth, and a cervical length 20 mm. Despite using a low prevalence of cervical length 20 mm in the model (0.83%), this intervention continued to be cost-effective when compared to routine care.
In 2016, Einerson et al 96 reported that universal transvaginal cervical length screening of women with no previous spontaneous preterm birth and treatment with vaginal progesterone to those with a cervical length 20 mm was more cost-effective in comparison to both risk-based screening and no screening of transvaginal cervical length. Crosby et al 97 reported that universal cervical length screening and treatment with vaginal progesterone to women with a cervical length 15 mm in a population at low risk of preterm birth in Ireland would reduce the rate of preterm birth <34 weeks of gestation by 28% and would be cost-effective. Pizzi et al 98 performed an economic analysis of the PREGNANT trial 72 and found that vaginal progesterone was both costsaving and cost-effective as compared to placebo. A cost-effectiveness analysis of universal cervical length screening in women without a previous spontaneous preterm birth and treatment with vaginal progesterone to those with a short cervix (cervical length 20 mm) reported that this intervention would be cost-effective if vaginal progesterone reduces the risk of preterm birth <33 weeks of gestation by >36%. 99 In our IPD meta-analysis, vaginal progesterone decreased the risk of preterm birth <33 weeks of gestation by 38%. Finally, 5 cost-effectiveness and decision analyses published only in abstract form also reported that vaginal progesterone administration was a cost-effective strategy for preventing preterm birth in women with a short cervix.
100-104
Implementation of universal cervical length screening and vaginal progesterone administration to patients with a sonographic short cervix 106 concluded that universal midtrimester transvaginal cervical length screening for women with a singleton gestation, followed by treatment with vaginal progesterone for those with a short cervix, meets all 10 criteria outlined by the World Health Organization for endorsing the implementation of a screening test in clinical medicine. 107 Based on the totality of evidence, we and others have recommended universal transvaginal cervical length screening at 18-24 weeks of gestation in women with a singleton gestation and the administration of vaginal progesterone for those with a sonographic short cervix. 52, 57, 105, 106, [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] In 2016, Son et al 119 reported on the results of introducing a universal transvaginal cervical length screening program for women with a singleton gestation without a previous preterm birth and treatment with vaginal progesterone to those with a cervical length 20 mm at Northwestern Memorial Hospital in Chicago, IL (46,598 women in the prescreening group and 17,609 in the screened group). The implementation of this program was associated with a significant reduction in the rates of preterm birth <37, <34, and <32 weeks of gestation when compared to preterm birth rates before implementation of the program. These significant differences were driven by a reduction in spontaneous preterm births. Furthermore, these reductions were similar in both nulliparous and parous women.
Similarly, Temming et al 120 evaluated the implementation of a universal ajog.org Reports of Major Impact transvaginal cervical length screening program for women with a singleton gestation followed by treatment with vaginal progesterone to those with a cervical length 20 mm in St Louis, MO. The rates of preterm birth <24 and <28 weeks of gestation were significantly lower among women who underwent cervical length screening (N ¼ 9731) than those patients who did not participate in the screening program (N ¼ 1661). There was also a nonsignificant reduction in the rate of preterm birth <34 weeks of gestation among screened women.
A smaller study that assessed a similar program for women with a singleton gestation without a history of spontaneous preterm birth at a single institution in Philadelphia, PA, reported that the rate of spontaneous preterm birth was similar between women undergoing transvaginal cervical length screening (N ¼ 1569) and those not screened (N ¼ 602). 121 However, that study was underpowered to detect differences in spontaneous preterm birth rates between the study groups. Schoen et al 122 assessed the reasons behind the decrease in preterm birth rates in the United States during the last 7 years and suggested that the use of vaginal progesterone in pregnant women with a short cervix is one of the interventions that contributed to this reduction.
Recently, Newnham et al 123 reported the results of a prospective populationbased cohort study that evaluated the effects of implementation of a statewide multifaceted program on the preterm birth rates in Western Australia before and after the first full year of operation. One of the key interventions of the program was the universal cervical length measurement at 18-20 weeks of gestation in women with a singleton gestation and treatment with vaginal progesterone to those with a cervical length 25 mm. The implementation of the program in 2014 was followed by a statistically significant 7.6% reduction in the rate of preterm birth in 2015, which was lower than in any of the preceding 6 years. The effect extended from the 28-to 31-week gestational age group onward. Further studies are required to elucidate the precise contribution of the different elements of the program to the reduction in preterm birth.
Based on current national vital statistics 2 and the results of our IPD meta-analysis, we estimated that the implementation of universal transvaginal cervical length screening in women with a singleton gestation in the United States and treatment with vaginal progesterone to those with a short cervix (cervical length 25 mm) would result in an annual reduction of approximately 31,800 preterm births <34 weeks of gestation and of 19,800 cases of major neonatal morbidity or neonatal mortality if the overall prevalence of a short cervix is 9%, 13 and of approximately 7000 preterm births <34 weeks of gestation and of 4400 cases of major neonatal morbidity or neonatal mortality if the overall prevalence of a short cervix is 2%. 120 The effects of progesterone on the uterine cervix Progesterone is critical for pregnancy maintenance, and a withdrawal of progesterone action is believed to be central to the initiation of parturition in most mammalian species, including primates. [124] [125] [126] [127] [128] [129] [130] [131] Progesterone exerts biological effects in the myometrium, [132] [133] [134] [135] [136] chorioamniotic membranes, 137 and uterine cervix (ie, control of cervical remodeling). 138, 139 Progesterone withdrawal (in rats, rabbits, and sheep) or a decline in progesterone action (in guinea pigs and primates) 129 has been proposed as a key control mechanism for cervical ripening by Xu et al, 140 Nold et al, 141 Mahendroo et al, 142, 143 Word et al, 144 Kirby et al, 145 Yellon et al, 146, 147 and Chwalisz et al. [148] [149] [150] Thus, a large body of evidence supports a role for progesterone in cervical remodeling. [151] [152] [153] [154] [155] [156] [157] [158] For example: (1) administration of antiprogestins to women in the midtrimester and at term induces cervical ripening; [151] [152] [153] [154] [155] [156] [157] [158] and (2) administration of progesterone-receptor antagonists such as mifepristone (RU486) or onapristone to pregnant guinea pigs, 159 old-world monkeys, 160 and Tupaja belangeri induces cervical ripening. 144 It is interesting that cervical responsiveness to antiprogestins increases with advancing gestational age 144 and that their effects on the cervix are not always accompanied by changes in myometrial activity. 144 Indeed, Stys et al 161 demonstrated a functional dissociation between the effects of progesterone in the myometrium and those in the cervix. Collectively, the evidence indicates that a major site of progesterone action is the uterine cervix.
A decline in progesterone action probably causes cervical changes by inducing changes in extracellular matrix metabolism, and perhaps inflammation (leukocyte infiltration and production of chemokines 162 such as interleukin-8, 139 nitric oxide, 150, 157 prostaglandins, 139 and matrix-degrading enzymes). 163, 164 It is also possible that cervical remodeling is influenced by nuclear factor (NF)-kB, a transcription factor that mediates the effect of certain proinflammatory cytokines such as interleukin-1b [165] [166] [167] [168] and tumor necrosis factor-a. [169] [170] [171] This is potentially relevant because NF-kB can oppose progesterone action. 132, 167, [172] [173] [174] Thus, NF-kB could provide a link among inflammation, a decline in progesterone action and cervical remodeling.
The traditional understanding of the mechanisms of progesterone action is that this hormone functions through nuclear receptors to prompt genomic processes. [175] [176] [177] [178] [179] [180] [181] [182] However, it is now clear that some progesterone actions in pregnancy are induced through membrane receptors and nongenomic mechanisms. [183] [184] [185] [186] [187] The precise roles of progesterone receptors, deoxyribonucleic acid-binding properties, and/or transcriptional activity in determining the mechanisms of progesterone action on the cervix remain to be elucidated.
Another unresolved issue is why progesterone administration to pregnant women, who already have a very high concentration of circulating progesterone, 144 would result in a therapeutic effect. In fact, it has been argued that the circulating concentration of progesterone in pregnant women is in excess of that required to saturate progesterone receptors. 144 However, these biochemical considerations were developed before the realization that some actions Reports of Major Impact ajog.org of progesterone are independent of its nuclear receptors. 188, 189 It is possible that the change in progesterone concentrations at the time of spontaneous parturition in the human occurs locally and not in the systemic circulation. 190, 191 Recently, the laboratories of Lye and Mesiano [192] [193] [194] have provided evidence in support of a novel mechanism whereby a functional progesterone withdrawal could occur in the myometrium, independent of a progesterone concentration in the peripheral circulation. Whether this specific mechanism is operational in the uterine cervix remains to be determined.
A recent study 195 about the mechanisms of action of progestogens in vivo has shown that vaginal progesterone has local antiinflammatory effects at the maternal-fetal interface. Specifically, when vaginal progesterone is administered to pregnant mice, it fosters an antiinflammatory microenvironment at the maternal-fetal interface by increasing CD4
þ Tregs and reducing CD8 þ
CD25
þ Foxp3 þ T cells, macrophages, and interferon g þ neutrophils. 195 In addition, the administration of vaginal progesterone decreases the infiltration of active matrix metalloproteinase-9 þ neutrophils and monocytes in the cervix, reduces the plasma concentration of interleukin-1b, and reduces the frequency of endotoxininduced preterm birth. 195 In summary, progesterone has antiinflammatory effects and also modulates other biological processes implicated in cervical ripening.
Conclusions
There is persuasive evidence that vaginal progesterone reduces the risk of preterm birth and adverse perinatal outcomes in patients with a singleton gestation and a midtrimester short cervix, regardless of the history of spontaneous preterm birth, without any demonstrable deleterious effects on childhood neurodevelopment or maternal health. The findings of our meta-analysis of IPD should reassure clinicians and professional/scientific organizations that vaginal progesterone is efficacious and safe for reducing preterm birth and neonatal morbidity and mortality in these women. In addition, recent evidence assessing the implementation of universal cervical length screening in women with a singleton gestation and treatment with vaginal progesterone to those with a short cervix suggests that this intervention could contribute to a reduction in the rate of preterm birth and associated neonatal morbidity and mortality in the United States. n
